Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Chat with Yara.AI
Your financial questions, answered anytime, instantly.
Cibil Report
Get cibil report
Do not call
En
Jagsonpal Pharmaceuticals Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹214.14
High
₹217.50
Price Summary
| Previous Close | ₹216.15 |
|---|---|
| Day's Range | ₹214.14 - ₹217.50 |
| Open | ₹217.00 |
| 52 Week Range | ₹155.00 - ₹264.50 |
| Volume | 24,541 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 52.98 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 2.55 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | 0.00 |
| P/E Ratio | |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | |
| Face Value (₹) | 2.00 |
| ROCE(%) |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 744.65 | 2687.16 |
| Expenses | N/A | N/A |
| PBT | 168.1 | 698.59 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 125.74 | 553.61 |
About Jagsonpal Pharmaceuticals Ltd.
| Founded | 1978 |
|---|---|
| Managing Director | Manish Gupta |
| NSE Symbol | JAGSNPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,290.91 | 1,880.90 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 3,05,014.11 | 11,489.65 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,77,333.20 | 4,662.15 | 3,672.30 - 3,672.30 |
| Laurus Labs Ltd. | 1,30,755.56 | 2,420.00 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,26,550.66 | 726.30 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,22,439.82 | 8,515.50 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,18,802.71 | 1,191.00 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,15,016.89 | 1,377.00 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,12,538.81 | 1,393.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,09,622.17 | 2,654.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Aug
28
2026
Posted on Aug 28th 2026
Jagsonpal Pharmaceuticals informs about newspaper advertisement
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Jagsonpal Pharmaceuticals has informed that it enclosed the copy of newspaper advertisement published in newspapers, Business Standard (in English) and Business Standard (in Hindi) on August 28, 2026 regarding Notice of 47th Annual General Meeting of the Company sent to the members.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
24
2026
Posted on Aug 24th 2026
Jagsonpal Pharmaceuticals informs about allotment of ESOP
Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Jagsonpal Pharmaceuticals has informed that the Nomination and Remuneration Committee has issued and allotted 27,950 Equity Shares of Rs 2 each under JPL ESOP 2022, to the eligible employees of the Company, upon exercise of vested options. These shares shall rank Pari-passu with the existing equity shares of the Company, in all respects. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs 13,18,58,940 (constituting of 6,59,29,470 equity shares of Rs 2 each) to Rs 13,19,14,840 (constituting of 6,59,57,420 equity shares of Rs 2 each). Details under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, is attached.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
14
2026
Posted on Nov 14th 2026
Natco Pharma - Quaterly Results
The Sales for the quarter ended September 2026 of Rs. 8545.00 million declined by -32.41% from Rs. 12643.00 millions.Net profit of the cmpany stood at Rs. 1432.00 millions for the quarter ended September 2026 a decline of -71.41% from Rs. 5009.00 millions in the same quarter last year.The Operating Profit of the company witnessed a decrease to 2566.00 millions from 6458.00 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 8545.00 | 12643.00 | -32.41 | 14511.00 | 24570.00 | -40.94 | 35946.00 | 40945.00 | -12.21 |
| Other Income | 403.00 | 933.00 | -56.81 | 886.00 | 1529.00 | -42.05 | 2811.00 | 3213.00 | -12.51 |
| PBIDT | 2566.00 | 6458.00 | -60.27 | 4109.00 | 12451.00 | -67.00 | 15860.00 | 24656.00 | -35.67 |
| Interest | 156.00 | 117.00 | 33.33 | 252.00 | 143.00 | 76.22 | 323.00 | 196.00 | 64.80 |
| PBDT | 2410.00 | 6341.00 | -61.99 | 3857.00 | 12308.00 | -68.66 | 15537.00 | 24460.00 | -36.48 |
| Depreciation | 440.00 | 481.00 | -8.52 | 867.00 | 1019.00 | -14.92 | 1896.00 | 2200.00 | -13.82 |
| PBT | 1970.00 | 5860.00 | -66.38 | 2990.00 | 11289.00 | -73.51 | 13641.00 | 22260.00 | -38.72 |
| TAX | 538.00 | 851.00 | -36.78 | 812.00 | 1639.00 | -50.46 | 826.00 | 3756.00 | -78.01 |
| Deferred Tax | 314.00 | -455.00 | -169.01 | 478.00 | -727.00 | -165.75 | -1858.00 | -319.00 | 482.45 |
| PAT | 1432.00 | 5009.00 | -71.41 | 2178.00 | 9650.00 | -77.43 | 12815.00 | 18504.00 | -30.74 |
| Equity | 358.00 | 358.00 | 0.00 | 358.00 | 358.00 | 0.00 | 358.00 | 358.00 | 0.00 |
| PBIDTM(%) | 30.03 | 51.08 | -41.21 | 28.32 | 50.68 | -44.12 | 44.12 | 60.22 | -26.73 |
Read More
Nov
14
2026
Posted on Nov 14th 2026
Park Medi World - Quaterly Results
A decent increase of about 48.26% in the sales to Rs. 340.54 millions was observed for the quarter ended September 2026. The sales figure stood at Rs. 229.69 millions during the year-ago period.The Net Loss for the quarter ended September 2026 is Rs. -6.57 millions as compared to Net Profit of Rs. 48.96 millions of corresponding quarter ended September 2025A decline of 54.72 millions was observed in the OP in the quarter ended September 2026 from 105.50 millions on QoQ basis.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 340.54 | 229.69 | 48.26 | 675.86 | 459.38 | 47.12 | 1289.65 | 915.82 | 40.82 |
| Other Income | 41.70 | 2.00 | 1985.00 | 88.38 | 4.01 | 2103.99 | 103.35 | 20.70 | 399.28 |
| PBIDT | 54.72 | 105.50 | -48.13 | 114.24 | 211.02 | -45.86 | 627.05 | 261.09 | 140.17 |
| Interest | 17.23 | 32.97 | -47.74 | 25.83 | 65.95 | -60.83 | 127.55 | 123.43 | 3.34 |
| PBDT | 37.49 | 72.53 | -48.31 | 88.41 | 145.07 | -39.06 | 499.50 | 137.66 | 262.85 |
| Depreciation | 43.61 | 11.62 | 275.30 | 77.42 | 23.23 | 233.28 | 45.09 | 48.62 | -7.26 |
| PBT | -6.12 | 60.91 | -110.05 | 10.99 | 121.84 | -90.98 | 454.41 | 89.04 | 410.34 |
| TAX | 0.45 | 11.95 | -96.23 | 6.72 | 23.91 | -71.89 | 88.25 | 17.24 | 411.89 |
| Deferred Tax | -2.59 | -0.13 | 1892.31 | 0.24 | -0.26 | -192.31 | -24.50 | -20.83 | 17.62 |
| PAT | -6.57 | 48.96 | -113.42 | 4.27 | 97.93 | -95.64 | 366.16 | 71.80 | 409.97 |
| Equity | 863.86 | 768.80 | 12.36 | 863.86 | 768.80 | 12.36 | 863.86 | 768.80 | 12.36 |
| PBIDTM(%) | 16.07 | 45.93 | -65.02 | 16.90 | 45.94 | -63.20 | 48.62 | 28.51 | 70.55 |
Read More
Nov
14
2026
Posted on Nov 14th 2026
KMC Speciality Hosp. - Quaterly Results
The company witnessed a 24.08% growth in the revenue at Rs. 929.37 millions for the quarter ended September 2026 as compared to Rs. 749.02 millions during the year-ago period.A good growth in profit of 49.64% reported to Rs. 162.23 millions over Rs. 108.41 millions of corresponding previous quarter.Operating Profit saw a handsome growth to 297.61 millions from 220.89 millions in the quarter ended September 2026.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 929.37 | 749.02 | 24.08 | 1847.14 | 1414.55 | 30.58 | 3057.68 | 2315.98 | 32.03 |
| Other Income | 14.58 | 12.44 | 17.20 | 32.66 | 20.45 | 59.71 | 50.76 | 30.86 | 64.48 |
| PBIDT | 297.61 | 220.89 | 34.73 | 600.54 | 393.41 | 52.65 | 930.02 | 599.71 | 55.08 |
| Interest | 19.31 | 20.45 | -5.57 | 39.34 | 42.09 | -6.53 | 83.07 | 94.16 | -11.78 |
| PBDT | 278.30 | 200.44 | 38.84 | 561.20 | 351.32 | 59.74 | 846.95 | 505.55 | 67.53 |
| Depreciation | 61.92 | 53.04 | 16.74 | 120.44 | 103.86 | 15.96 | 216.71 | 189.52 | 14.35 |
| PBT | 216.38 | 147.40 | 46.80 | 440.76 | 247.46 | 78.11 | 630.24 | 316.03 | 99.42 |
| TAX | 54.15 | 38.99 | 38.88 | 112.80 | 63.70 | 77.08 | 162.89 | 101.76 | 60.07 |
| Deferred Tax | -2.95 | 5.24 | -156.30 | -7.21 | -0.90 | 701.11 | 3.77 | 28.68 | -86.85 |
| PAT | 162.23 | 108.41 | 49.64 | 327.96 | 183.76 | 78.47 | 467.35 | 214.27 | 118.11 |
| Equity | 163.08 | 163.08 | 0.00 | 163.08 | 163.08 | 0.00 | 163.08 | 163.08 | 0.00 |
| PBIDTM(%) | 32.02 | 29.49 | 8.59 | 32.51 | 27.81 | 16.90 | 30.42 | 25.89 | 17.46 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Jagsonpal Pharmaceuticals Ltd. is ₹216.15 as of 2026-11-13.
The market capitalisation of Jagsonpal Pharmaceuticals Ltd. is ₹1,427.21 as of 2026-11-13.
The 1-year return of Jagsonpal Pharmaceuticals Ltd. is 5.94% as of 2026-11-13.
The P/E ratio of Jagsonpal Pharmaceuticals Ltd. is 28.65 as of 2026-11-15.
The 52-week high and low of Jagsonpal Pharmaceuticals Ltd. are ₹264.50 and ₹155.00, respectively, as of 2026-11-13.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
